Who are Probucol and Cilostazol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probucol-and-cilostazol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Probucol and Cilostazol — Competitive Intelligence Brief

Probucol and Cilostazol (Probucol and Cilostazol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor. Area: Cardiovascular.

marketed Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor Probucol: lipid peroxidation inhibitor; Cilostazol: phosphodiesterase-3 (PDE-3) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Probucol and Cilostazol (Probucol and Cilostazol) — Otsuka Beijing Research Institute. This combination of probucol (an antioxidant lipid-lowering agent) and cilostazol (a phosphodiesterase-3 inhibitor with antiplatelet and vasodilatory properties) works synergistically to reduce lipid oxidation, improve blood flow, and inhibit platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Probucol and Cilostazol TARGET	Probucol and Cilostazol	Otsuka Beijing Research Institute	marketed	Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor	Probucol: lipid peroxidation inhibitor; Cilostazol: phosphodiesterase-3 (PDE-3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor class)

Otsuka Beijing Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Probucol and Cilostazol — Competitive Intelligence Brief. https://druglandscape.com/ci/probucol-and-cilostazol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab